A genetic variation in how the metabolite of the cancer drug ...

[strangeaffliction]

A genetic variation in how the metabolite of the cancer drug irinotecan SN-38 is inactivated by the body may lead to:
 
  1. Decreased effectiveness of irinotecan in the treatment of cancer
  2. Increased adverse drug reactions, such as neutropenia
  3. Delayed metabolism of the prodrug irinotecan into the active metabolite SN-38
  4. Increased concerns for irinotecan being carcinogenic

Question 2

Patients who have a poor metabolism phenotype will have:
 
  1. Slowed metabolism of a prodrug into an active drug, leading to accumulation of prodrug
  2. Accumulation of inactive metabolites of drugs
  3. A need for increased dosages of medications
  4. Increased elimination of an active drug

[jordangronback]

Answer to Question 1

2

Answer to Question 2

1

[strangeaffliction]

TY

[jordangronback]

You're welcome